Compass was developed by L2S2 on the MMDC / Reassure platform. L2S2 has encapsulated C2-Ai’s AI with a secure wrapper that protects the IP and delivered as a Class 1 medical device app in a few months.
C2-Ai will also be at the forefront of companies helping the NHS to recover normal services. C2-Ai’s surgical triage app, COMPASS, also developed by L2S2 using the MMDC Reassure platform will be used to prioritise the growing (currently10 million strong) waiting list. This app objectively scores the individual’s risk of mortality and complications, by providing bespoke risk assessments for complications and mortality in less than a minute. It provides a suite of risk assessments for different conditions and procedures creating opportunities to optimise care prior to surgery.
Compass was produced rapidly by L2S2 using MMDC. It encapsulates AI algorithms developed using more than 100m health records and has been registered as a Class I medical device by L2S2 using MMDC.
L2S2 is proud to be helping C2-Ai to keep patients safe.
The Arm / L2S2 partnership overcomes many of these barriers to healthtech development and deployment. It provides a trusted ecosystem of highly configurable solutions.
L2S2 is a specialist supplier of compliant solutions for the highly regulated healthcare market. L2S2’s solutions accelerate development and deployment of new medical-device-grade software products. They ensure compliant data management ‘out of the box’, connect to established healthcare IT systems and reduce product life cycle costs. L2S2’s Reassure products also provide a channel to market for new entrants.
The partnership extends L2S2’s solutions with the power of Arm’s mbed IoT operating system and Arm’s Pelion IoT platform for device management and secure data transfer. Combined, the Arm and L2S2 technologies can greatly accelerate delivery of compliant healthcare at scale.
Compass was developed by L2S2 on the MMDC / Reassure platform. L2S2 has encapsulated C2-AI’s AI with a secure wrapper that protects the IP and delivered as a Class 1 medical device app in a few months.
C2-AI will also be at the forefront of companies helping the NHS to recover normal services. C2-AI’s surgical triage app, COMPASS, also developed by L2S2 using the MMDE Reassure platform will be used to prioritise the growing (currently10 million strong) waiting list. This app objectively scores the individual’s risk of mortality and complications, by providing bespoke risk assessments for complications and mortality in less than a minute. It provides a suite of risk assessments for different conditions and procedures creating opportunities to optimise care prior to surgery.
Compass was produced rapidly by L2S2 using MMDC. It encapsulates AI algorithms developed using more than 100m health records and has been registered as a Class I medical device by L2S2 using MMDC.
L2S2 is proud to be helping C2-AI to keep patients safe.
